Share This 
Mr. Marasco Brings More Than 22 Years of Experience in Global Commercial and Business Development within the Pharmaceutical and Biotech Industries
DECEMBER 12, 2019—Durham, NC—BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, has welcomed Dominic “Nick” Marasco, R.Ph., to its leadership team as Chief Commercial Officer. In this role, Mr. Marasco will provide strategic direction to BioAgilytix’s global business development and marketing functions / teams to further expand worldwide adoption of the company’s premier bioanalytical services.
Mr. Marasco brings with him more than 22 years of executive experience in C-suite strategy development, commercial operations, strategic business development, alliance management, and financial resourcing within the Pharmaceutical, Biotech and Medical Device industries. Just prior to joining BioAgilytix, he served as Executive Vice President, Global Business Development, Commercial at Syneos Health, where he led the overall strategic direction of the global business development team for the commercial division both in the U.S. and internationally. He was also previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc. and prior to that Global Commercial Head, Amgen Biosimilars. Mr. Marasco has also held executive-level commercial and business development positions at Sandoz Biopharmaceuticals (a Novartis company) and Quintiles Translational Corporation. Mr. Marasco is a member of the Health Policy and Management Executive Council at the Harvard T.H. Chan School of Public Health and is a University of Southern California Adjunct Associate Professor of Pharmaceuticals and Health Economics for the School of Pharmacy. He received his Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and is a registered pharmacist with a current active licensure.
“I’m thrilled to have Nick join BioAgilytix and have no doubt that he will continue to extend his impressive track record of commercial and business development success as part of our team,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “He will help to methodically scale our commercial operations to support sponsors’ increasing need for expert-level bioanalysis, and to ensure we can help our customers get safe, effective large molecule drug innovations to market quickly. His wealth of experience on both the service side and sponsor side of the pharma and biotech industry, as well as his deep knowledge of the global commercial landscape, will help inform our strategies as we seek to solidify our position as the best-in-class large molecule bioanalytical service provider worldwide.”
“The stellar reputation that BioAgilytix has built is backed not only by its seasoned leadership but by the commitment and dedication of its entire team. I couldn’t be more excited to join them as we look to expand on the company’s global success,” said Mr. Marasco. “I look forward to executing the strategies that will ensure BioAgilytix is the known, preferred choice for any sponsor in need of deep and specialized expertise in large molecule bioanalysis.”
###
About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With US headquarters in North Carolina’s Research Triangle area, a laboratory in Boston, Massachusetts, and European headquarters in Hamburg, Germany, BioAgilytix provides global services for biomarkers, immunogenicity, PK, and cell-based assays supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.). We also offer diagnostic testing services through our Boston, MA laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit www.bioagilytix.com.
Media Contact:
Jennifer Absher
BioAgilytix
(919) 287-1573
[email protected]
